A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Latest Information Update: 08 Nov 2022
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms BOOST
- 04 Nov 2022 Primary endpoint (Progression-free survival rate) has not been met, according to Results published in the Journal of Clinical Oncology.
- 04 Nov 2022 Results published in the Journal of Clinical Oncology
- 08 Jun 2021 Interim results (n=927) presented at the 57th Annual Meeting of the American Society of Clinical Oncology